MedPath

Nuedexta

These highlights do not include all the information needed to use NUEDEXTA safely and effectively. See full prescribing information for NUEDEXTA. NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, for oral use Initial U.S. Approval: 2010

Approved
Approval ID

c8cce784-8c5f-415b-8068-76e5d481d159

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 13, 2023

Manufacturers
FDA

Otsuka America Pharmaceutical, Inc

DUNS: 008314390

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dextromethorphan hydrobromide and quinidine sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59148-053
Application NumberNDA021879
Product Classification
M
Marketing Category
C73594
G
Generic Name
dextromethorphan hydrobromide and quinidine sulfate
Product Specifications
Route of AdministrationORAL
Effective DateDecember 31, 2022
FDA Product Classification

INGREDIENTS (2)

dextromethorphan hydrobromideActive
Quantity: 20 mg in 1 1
Code: 9D2RTI9KYH
Classification: ACTIB
QUINIDINE SULFATEActive
Quantity: 10 mg in 1 1
Code: J13S2394HE
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Nuedexta - FDA Drug Approval Details